AB
Arbutus Biopharma Corp
ABUS · NASDAQ
$5.01 -0.60% (-$0.03)
1M -3.85%
Market Cap $987.7M
P/E Ratio 6.45x
Div. Yield -
ROE 90.98%
Bulios Fair Price
$4.53
9.6% downside
Current Price
$5.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ABUS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
82 /100
Cheap EV/EBITDA 6.35x
P/S 5.44x
P/B 3.82x
Growth
0 /100
Declining Book val. growth 17.60%
Rev. growth 28.80%
FCF growth N/A
Profitability
70 /100
Strong Net margin 84.23%
Op. margin 81.01%
FCF margin 13.55%
Quality
93 /100
Excellent ROE 90.98%
ROA 55.85%
Asset turnover 0.66x
Debt
100 /100
Low Current ratio 81.42x
Int. coverage 2,014.87x
Net debt/EBITDA -0.10x
Stability
47 /100
Moderate Rev. volatility 108.70%
EPS volatility 27.12%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ABUS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lindsay Androski
Employees
19
Headquarters
Warminster
Upcoming events
16 NOV
Earnings
Upcoming earnings report